Rocket Pharmaceuticals Inc (RCKT)

$2.86 +0.05 (1.78%)
Market Cap 325.70M
Revenue (ttm) 0.00
Net Income (ttm) -258.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,587,703
Avg Vol 5,356,514
Day's Range N/A - N/A
Shares Out 106.79M
Stochastic %K 35%
Beta 0.67
Analysts Sell
Price Target $9.03

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
darntootin
darntootin Jul. 16 at 9:48 AM
$RCKT https://www.cellandgene.com/doc/luxturna-maker-spark-therapeutics-flexible-platform-approach-0001 Good read on Chris Steven’s
0 · Reply
darntootin
darntootin Jul. 16 at 9:47 AM
$RCKT The clinical hold seems to be the focus of everyone’s attention but in my opinion the CRL letter is what’s really important here it has been over a year the FDA asked for more information about chemistry manufacturing and controls since then the company has appointed Mikael dolston to the board who is the head of research and development at Pfizer focused on gene therapies and recently a new addition Chris Stevens who until recently was chief patient supply officer at Spark Therapeutics, which he joined in 2017 to lead all internal and external drug product and drug substance manufacturing. Pfizer and spark have been working together for over a decade on gene therapies I don’t think it’s a coincidence Chris Steven’s was just made COO manufacturing these cures is a complicated process and this guy can get it done Pfizer is very interested in what’s going on here just my thoughts everything points in the right direction for me gl
1 · Reply
sepsis74
sepsis74 Jul. 15 at 3:08 PM
$IOVA $RCKT $GERN Goldman has an awful lot of sell recommendations out on biotechs that have already gotten crushed. It's like they have a directive out. Hope they get burned badly by a rebound in the whole sector.
4 · Reply
Stockseeking
Stockseeking Jul. 14 at 11:49 PM
$RCKT Estimated timline 1. May 27 received clinical trial hold notice. 2. RCKT most likely started working on a response to lift hold 3. June 27 received FDA written letter of clinical hold 4. Assuming RCKT spent a couple of days to revise the draft response to align with FDA written letter, response was submitted around July 1 st 5. FDA has 30-day to respond so lift of clinical hold could be announced by the end of July if not earlier Disclaimer: Not recommendation to invest, just want to share my thought
1 · Reply
11thestate
11thestate Jul. 14 at 5:14 PM
$RCKT stockholders filed a claim against Rocket Pharma for allegedly hiding fatal risks in its gene therapy trial and misleading investors about its Danon disease program. You can join this case to be notified about any new information: https://11th.com/cases/rocketpharma-investor-suit
4 · Reply
Stockseeking
Stockseeking Jul. 14 at 3:03 PM
$RCKT Waiting for the first news of clinical trial hold lift to 2x sp. RCKT was notified on May 27, news could come any day now
0 · Reply
geegor
geegor Jul. 11 at 8:49 PM
$RCKT Christopher Stevens appointed Chief Operating Officer. Dr. Kinnari Patel transitions from Chief Operating Officer, President and Head of R&D to President, Head of R&D. https://ir.rocketpharma.com/node/12706/html The separation of these two important functions looks like a sign of maturity and progress to me. With six clinical/preclinical programs on the go, trying to juggle R&D with growing operational & commercial objectives was always going to become a tall order.
1 · Reply
beelovjazz
beelovjazz Jul. 11 at 7:41 PM
$RCKT why is it so hard for the company to update investors on the review process
2 · Reply
geegor
geegor Jul. 11 at 7:22 PM
$RCKT 💰
0 · Reply
80proof
80proof Jul. 11 at 4:19 PM
$RCKT you’re going to have to deal with dilution. You do realize that don’t you? It won’t be just a one time thing either.
1 · Reply
Latest News on RCKT
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 11, 2025, 10:25 AM EDT - 5 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 6 days ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jul 7, 2025, 9:00 AM EDT - 9 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 3, 2025, 7:50 AM EDT - 13 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 16 days ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jun 24, 2025, 11:29 AM EDT - 22 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 4 weeks ago

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation

Jun 11, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Connect

Jun 10, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Reach Out

Jun 9, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Investors to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Investors to Learn More About the Investigation

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 6, 2025, 10:00 AM EDT - 5 weeks ago

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Connect

Jun 5, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Stockholders to Inquire about Securities Investigation

Jun 4, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Stockholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation

Jun 1, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Reach Out

May 30, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Reach Out

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

May 29, 2025, 6:44 PM EDT - 6 weeks ago

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

darntootin
darntootin Jul. 16 at 9:48 AM
$RCKT https://www.cellandgene.com/doc/luxturna-maker-spark-therapeutics-flexible-platform-approach-0001 Good read on Chris Steven’s
0 · Reply
darntootin
darntootin Jul. 16 at 9:47 AM
$RCKT The clinical hold seems to be the focus of everyone’s attention but in my opinion the CRL letter is what’s really important here it has been over a year the FDA asked for more information about chemistry manufacturing and controls since then the company has appointed Mikael dolston to the board who is the head of research and development at Pfizer focused on gene therapies and recently a new addition Chris Stevens who until recently was chief patient supply officer at Spark Therapeutics, which he joined in 2017 to lead all internal and external drug product and drug substance manufacturing. Pfizer and spark have been working together for over a decade on gene therapies I don’t think it’s a coincidence Chris Steven’s was just made COO manufacturing these cures is a complicated process and this guy can get it done Pfizer is very interested in what’s going on here just my thoughts everything points in the right direction for me gl
1 · Reply
sepsis74
sepsis74 Jul. 15 at 3:08 PM
$IOVA $RCKT $GERN Goldman has an awful lot of sell recommendations out on biotechs that have already gotten crushed. It's like they have a directive out. Hope they get burned badly by a rebound in the whole sector.
4 · Reply
Stockseeking
Stockseeking Jul. 14 at 11:49 PM
$RCKT Estimated timline 1. May 27 received clinical trial hold notice. 2. RCKT most likely started working on a response to lift hold 3. June 27 received FDA written letter of clinical hold 4. Assuming RCKT spent a couple of days to revise the draft response to align with FDA written letter, response was submitted around July 1 st 5. FDA has 30-day to respond so lift of clinical hold could be announced by the end of July if not earlier Disclaimer: Not recommendation to invest, just want to share my thought
1 · Reply
11thestate
11thestate Jul. 14 at 5:14 PM
$RCKT stockholders filed a claim against Rocket Pharma for allegedly hiding fatal risks in its gene therapy trial and misleading investors about its Danon disease program. You can join this case to be notified about any new information: https://11th.com/cases/rocketpharma-investor-suit
4 · Reply
Stockseeking
Stockseeking Jul. 14 at 3:03 PM
$RCKT Waiting for the first news of clinical trial hold lift to 2x sp. RCKT was notified on May 27, news could come any day now
0 · Reply
geegor
geegor Jul. 11 at 8:49 PM
$RCKT Christopher Stevens appointed Chief Operating Officer. Dr. Kinnari Patel transitions from Chief Operating Officer, President and Head of R&D to President, Head of R&D. https://ir.rocketpharma.com/node/12706/html The separation of these two important functions looks like a sign of maturity and progress to me. With six clinical/preclinical programs on the go, trying to juggle R&D with growing operational & commercial objectives was always going to become a tall order.
1 · Reply
beelovjazz
beelovjazz Jul. 11 at 7:41 PM
$RCKT why is it so hard for the company to update investors on the review process
2 · Reply
geegor
geegor Jul. 11 at 7:22 PM
$RCKT 💰
0 · Reply
80proof
80proof Jul. 11 at 4:19 PM
$RCKT you’re going to have to deal with dilution. You do realize that don’t you? It won’t be just a one time thing either.
1 · Reply
Olivia_Love
Olivia_Love Jul. 11 at 2:05 PM
$SANA $RCKT $KROS $NMRA
1 · Reply
Stockseeking
Stockseeking Jul. 11 at 12:27 PM
$RCKT May 27, RCKT was notified of clinical hold, they may start working on a response to this hold immediately after and then finalized the response around June 27, after alignment with FDA official hold letter. FDA has 30 days to respond. So, lift of clinical hold could occur any days now.
0 · Reply
geegor
geegor Jul. 10 at 10:23 PM
$RCKT Latest short report data out today, to 06/30:
0 · Reply
QuantInsider
QuantInsider Jul. 10 at 8:30 PM
Whoa, $RCKT is making some waves today! The options volume is totally off the charts—like, way higher than normal. It’s got me thinking there might be something cooking behind the scenes. Is this just a bunch of traders getting hyped up, or do we have some real action on our hands? Either way, I’m all ears for any theories floating around. What’s everyone thinking?
1 · Reply
Stockseeking
Stockseeking Jul. 10 at 3:09 PM
$RCKT Coming events to make you richer 1. Lift of clinical hold 2xsp 2. BLA resubmission 2xsp 3. Leading to BLA approval and approval >2x This is based on my research and my own investment, please do your own research and make your own decision for your own money
0 · Reply
DarkOrb
DarkOrb Jul. 10 at 3:13 AM
$RCKT Highest close since the drop. Looks promising that it'll start to fill some of the gap soon. Some positive news would help a lot.
1 · Reply
BadensBester
BadensBester Jul. 9 at 8:03 PM
$RCKT nice close
0 · Reply
80proof
80proof Jul. 9 at 7:58 PM
$RCKT No future. Just bleeding and falling! Splat!
1 · Reply
BobBijawklah
BobBijawklah Jul. 9 at 7:11 PM
$RCKT I think this sector of biotech is ultra speculative and high risk but the reward will be staggering if we see approvals . some small biotech will turn into a multi billion dollar giant like merck is with keytruda. will it be rocket lottery ticket chance but i think it is a good long term what the hell play
0 · Reply
Newtimmy
Newtimmy Jul. 9 at 4:54 PM
$RCKT Looking resl
0 · Reply
Newtimmy
Newtimmy Jul. 9 at 3:23 PM
$RCKT Bout to take a bite out of shorties ass
0 · Reply
Stockseeking
Stockseeking Jul. 9 at 3:22 PM
$RCKT if you know of any significant risks, please share, below is a series of positive catalysts 1. Lift of clinical hold 2. BLA resubmission 3. BLA approval
1 · Reply